Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
1
See Original
Report
14K Views
Comment
Sign in to post a comment
l w :
On December 14, US biopharmaceutical company Arvinas (Nasdaq: ARVN), which focuses on the development of protein-degrading therapies, announced the latest clinical data on its ongoing research on the PROTAC proteolytic agents ARV-471 and ARV-110.
l w : On December 14, US biopharmaceutical company Arvinas (Nasdaq: ARVN), which focuses on the development of protein-degrading therapies, announced the latest clinical data on its ongoing research on the PROTAC proteolytic agents ARV-471 and ARV-110.